Innovative CAR-T cells effectively target glioblastoma with reduced toxicity
Glioblastoma is the most common and aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective. In recent years, immunotherapies have given patients hope, albeit with relatively modest success. One research team has succeeded in identifying a specific marker, PTPRZ1, on the surface […]